Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.01
AXGN's Cash to Debt is ranked lower than
67% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. AXGN: 1.01 )
Ranked among companies with meaningful Cash to Debt only.
AXGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 376.39 Max: No Debt
Current: 1.01
Equity to Asset 0.22
AXGN's Equity to Asset is ranked lower than
91% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. AXGN: 0.22 )
Ranked among companies with meaningful Equity to Asset only.
AXGN' s Equity to Asset Range Over the Past 10 Years
Min: -4.23  Med: 0.61 Max: 0.91
Current: 0.22
-4.23
0.91
F-Score: 5
Z-Score: 0.63
M-Score: -1.95
WACC vs ROIC
5.63%
-145.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -33.91
AXGN's Operating margin (%) is ranked lower than
67% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.64 vs. AXGN: -33.91 )
Ranked among companies with meaningful Operating margin (%) only.
AXGN' s Operating margin (%) Range Over the Past 10 Years
Min: -1447.95  Med: -122.58 Max: 64.05
Current: -33.91
-1447.95
64.05
Net-margin (%) -48.87
AXGN's Net-margin (%) is ranked lower than
71% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.79 vs. AXGN: -48.87 )
Ranked among companies with meaningful Net-margin (%) only.
AXGN' s Net-margin (%) Range Over the Past 10 Years
Min: -1426.03  Med: -156.76 Max: 60.4
Current: -48.87
-1426.03
60.4
ROE (%) -1705.31
AXGN's ROE (%) is ranked lower than
100% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. AXGN: -1705.31 )
Ranked among companies with meaningful ROE (%) only.
AXGN' s ROE (%) Range Over the Past 10 Years
Min: -581  Med: -68.21 Max: 264.57
Current: -1705.31
-581
264.57
ROA (%) -44.99
AXGN's ROA (%) is ranked lower than
79% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.56 vs. AXGN: -44.99 )
Ranked among companies with meaningful ROA (%) only.
AXGN' s ROA (%) Range Over the Past 10 Years
Min: -128.2  Med: -57.42 Max: 173.62
Current: -44.99
-128.2
173.62
ROC (Joel Greenblatt) (%) -185.52
AXGN's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. AXGN: -185.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AXGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -35233.33  Med: -298.10 Max: 265933.33
Current: -185.52
-35233.33
265933.33
Revenue Growth (3Y)(%) 14.70
AXGN's Revenue Growth (3Y)(%) is ranked higher than
84% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. AXGN: 14.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AXGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.70 Max: 471.3
Current: 14.7
0
471.3
EBITDA Growth (3Y)(%) -20.00
AXGN's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. AXGN: -20.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AXGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.9  Med: 4.55 Max: 197.7
Current: -20
-47.9
197.7
EPS Growth (3Y)(%) -15.50
AXGN's EPS Growth (3Y)(%) is ranked lower than
76% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. AXGN: -15.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AXGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.5  Med: 7.10 Max: 259.4
Current: -15.5
-50.5
259.4
» AXGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AXGN Guru Trades in Q1 2015

Chuck Royce 8,000 sh (-33.33%)
» More
Q2 2015

AXGN Guru Trades in Q2 2015

Chuck Royce Sold Out
» More
Q3 2015

AXGN Guru Trades in Q3 2015

Jim Simons 78,500 sh (New)
» More
Q4 2015

AXGN Guru Trades in Q4 2015

Jim Simons 36,400 sh (-53.63%)
» More
» Details

Insider Trades

Latest Guru Trades with AXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 20.70
AXGN's P/B is ranked lower than
98% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. AXGN: 20.70 )
Ranked among companies with meaningful P/B only.
AXGN' s P/B Range Over the Past 10 Years
Min: 0.69  Med: 7.94 Max: 607.5
Current: 20.7
0.69
607.5
P/S 5.26
AXGN's P/S is ranked lower than
71% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. AXGN: 5.26 )
Ranked among companies with meaningful P/S only.
AXGN' s P/S Range Over the Past 10 Years
Min: 0.48  Med: 4.58 Max: 833.33
Current: 5.26
0.48
833.33
Current Ratio 9.45
AXGN's Current Ratio is ranked higher than
92% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. AXGN: 9.45 )
Ranked among companies with meaningful Current Ratio only.
AXGN' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.65 Max: 12.36
Current: 9.45
0.56
12.36
Quick Ratio 8.39
AXGN's Quick Ratio is ranked higher than
91% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. AXGN: 8.39 )
Ranked among companies with meaningful Quick Ratio only.
AXGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 3.25 Max: 10.61
Current: 8.39
0.35
10.61
Days Inventory 266.94
AXGN's Days Inventory is ranked lower than
79% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 134.42 vs. AXGN: 266.94 )
Ranked among companies with meaningful Days Inventory only.
AXGN' s Days Inventory Range Over the Past 10 Years
Min: 251.85  Med: 313.05 Max: 489.83
Current: 266.94
251.85
489.83
Days Sales Outstanding 63.88
AXGN's Days Sales Outstanding is ranked higher than
58% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 70.19 vs. AXGN: 63.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
AXGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.47  Med: 62.33 Max: 365
Current: 63.88
0.47
365
Days Payable 157.43
AXGN's Days Payable is ranked higher than
82% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 64.85 vs. AXGN: 157.43 )
Ranked among companies with meaningful Days Payable only.
AXGN' s Days Payable Range Over the Past 10 Years
Min: 123.12  Med: 167.05 Max: 256.21
Current: 157.43
123.12
256.21

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 29.79
AXGN's Price/Net Current Asset Value is ranked lower than
89% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. AXGN: 29.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AXGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.5  Med: 5.34 Max: 45.83
Current: 29.79
1.5
45.83
Price/Tangible Book 22.64
AXGN's Price/Tangible Book is ranked lower than
92% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 3.66 vs. AXGN: 22.64 )
Ranked among companies with meaningful Price/Tangible Book only.
AXGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.35  Med: 2.71 Max: 43.65
Current: 22.64
1.35
43.65
Price/Median PS Value 1.14
AXGN's Price/Median PS Value is ranked lower than
60% of the 248 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. AXGN: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
AXGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 0.46 Max: 34.38
Current: 1.14
0.06
34.38
Earnings Yield (Greenblatt) (%) -5.45
AXGN's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. AXGN: -5.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AXGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.45  Med: 227.30 Max: 33220.9
Current: -5.45
-5.45
33220.9

More Statistics

Revenue(Mil) $27
EPS $ -0.52
Beta0.30
Short Percentage of Float1.40%
52-Week Range $2.95 - 6.08
Shares Outstanding(Mil)30.08

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 39 55 76
EPS($) -0.34 -0.18 0.10
EPS without NRI($) -0.34 -0.18 0.10

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:GNMK, NAS:ELOS, MIL:ELN, NAS:RTIX, TSX:NVC, TSE:7777 » details
AxoGen Inc is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance Nerve Graft, which the Company believes is the first and only commercially available processed allograft nerve for bridging nerve discontinuities. AxoGuard Nerve Connector, is used as a coaptation aid to facilitate the tensionless repair of severed nerves, and AxoGuard Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. The Company's products are used by surgeons during surgical interventions to repair a wide variety of nerve injuries throughout the body. These injuries range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that originate in the neck) as well as nerve injuries caused by dental and other surgical procedures. Avance Nerve Graft provides surgeons bridging material with the micro-architecture of a human nerve. This structure is essential and allows for bridging nerve gaps or discontinuities up to 70mm in length. Additionally, Avance Nerve Graft has product and sales synergies with AxoGuard Nerve Protector and AxoGuard Nerve Connector. AxoGuard products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). Regenerative medical products enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or defective tissues, such as bone, tendons, dermis and other tissues of the body. AxoGen's products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.
» More Articles for AXGN

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: AxoGen Inc, Medley Capital Corp, Quantum Fuel Systems Technologies Worldw Dec 20 2014 

More From Other Websites
AxoGen reports 1Q loss May 04 2016
AxoGen reports 1Q loss May 04 2016
4:57 pm AxoGen reports Q1 in-line, reaffirms 2016 revenue guidance, raises gross margin outlook May 04 2016
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million May 04 2016
AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 04 2016
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million May 04 2016
AXOGEN, INC. Files SEC form 10-Q, Quarterly Report May 04 2016
Q1 2016 AxoGen Inc Earnings Release - After Market Close May 04 2016
AxoGen (AXGN) Enters Overbought Territory Apr 29 2016
AxoGen, Inc. to Report First Quarter Results Apr 20 2016
AxoGen, Inc. to Report First Quarter Results Apr 20 2016
AxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial... Apr 08 2016
AxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial... Apr 07 2016
AxoGen, Inc. Launches AcroVal(TM) Neurosensory & Motor Testing System Mar 30 2016
AXOGEN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Mar 18 2016
AXOGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 14 2016
Kevin Leach Appointed Vice President of Marketing of AxoGen, Inc. Mar 14 2016
AxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference Mar 09 2016
AXOGEN, INC. Financials Mar 08 2016
CFO Moves: Delphi Automotive, Hain Celestial Group, AxoGen Inc. Mar 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK